NP_000236.2
[Other Products]
NCBI GenBank Nucleotide #
|
[Other Products]
UniProt Primary Accession #
|
[Other Products]
UniProt Secondary Accession #
UniProt Related Accession #
Molecular Weight
85,745 Da
NCBI Official Full Name
hepatocyte growth factor receptor isoform b
NCBI Official Synonym Full Names
MET proto-oncogene, receptor tyrosine kinase
NCBI Protein Information
hepatocyte growth factor receptor; HGF receptor; HGF/SF receptor; met proto-oncogene tyrosine kinase; proto-oncogene c-Met; scatter factor receptor; tyrosine-protein kinase Met
UniProt Protein Name
Hepatocyte growth factor receptor
UniProt Synonym Protein Names
HGF/SF receptor; Proto-oncogene c-Met; Scatter factor receptor; SF receptor; Tyrosine-protein kinase Met
UniProt Synonym Gene Names
UniProt Entry Name
MET_HUMAN
NCBI Summary for MET
The proto-oncogene MET product is the hepatocyte growth factor receptor and encodes tyrosine-kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. Various mutations in the MET gene are associated with papillary renal carcinoma. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
UniProt Comments for MET
Met: a proto-oncogenic receptor tyrosine kinase with high affinity for hepatocyte growth factor. The primary single chain precursor protein is post-translationally cleaved to produce the 45 kDa alpha- and 145 kDa beta-subunits, which are disulfide linked to form the mature receptor. Ligand-binding induces autophosphorylation at multiple tyrosines, which recruit several downstream signaling components, including Gab1, c-Cbl and PI3 kinase. Activating point mutations cause hereditary papillary renal carcinoma. Mutations also seen in sporadic renal cell carcinoma and childhood hepatocellular carcinoma. Upregulation in carcinomas and sarcomas correlates with metastasis and poor outcome. Some gastric carcinomas harbor a translocation that creates an activated TPR-Met fusion protein. A small molecule inhibitor (PHA-665752) shows an effect in gastric carcinoma xenografts. Inhibitors: SU11274, PHA-665752, mAbs. Two alternatively spliced human isoforms have been reported.
Protein type: Oncoprotein; Membrane protein, integral; EC 2.7.10.1; Protein kinase, TK; Kinase, protein; Protein kinase, tyrosine (receptor); TK group; Met family
Chromosomal Location of Human Ortholog: 7q31
Cellular Component: cell surface; integral to plasma membrane; plasma membrane; basal plasma membrane; extracellular region; integral to membrane
Molecular Function: protein binding; protein-tyrosine kinase activity; hepatocyte growth factor receptor activity; protein phosphatase binding; ATP binding
Biological Process: axon guidance; skeletal muscle development; peptidyl-tyrosine phosphorylation; activation of MAPK activity; protein amino acid autophosphorylation; myoblast proliferation; muscle cell migration; myotube differentiation; hepatocyte growth factor receptor signaling pathway; signal transduction; liver development; glucose homeostasis; cell proliferation; cell surface receptor linked signal transduction; positive chemotaxis; branching morphogenesis of a tube; adult behavior; positive regulation of transcription from RNA polymerase II promoter; endothelial cell morphogenesis; brain development; placenta development
Disease: Hepatocellular Carcinoma; Renal Cell Carcinoma, Papillary, 1
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice. It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Products associated with MET recombinant protein
Pathways associated with MET recombinant protein
Diseases associated with MET recombinant protein
Organs/Tissues associated with MET recombinant protein
|